ALUR stock is currently trading at $6.99, down from its recent high of $11.29 after a 205% surge due to a fundraising announcement and clinical study plans. The bullish view stems from its innovative obesity treatment combining GLP-1 agonists with its Allurion Program, which could position it as a leader in the obesity market if successful. However, the stock's volatility and recent pullback suggest caution, with potential support around $6.00.